Certara
CERT Nasdaq Health Care Technology 金融 FY2019–FY2025
Certara's revenue rose 8.8% to $419 million in fiscal 2025. Its operating margin was 5.0%, up from −0.5% a year earlier. Free cash flow was $95 million, up 19.9%. It paid out $43 million in dividends and buybacks, 45% of free cash flow.
Certara 的业务
暂无业务介绍。
- 法定名称
- Certara, Inc.
- 财年结束日
- 2025年12月31日
- 最新年报
- —
- 登记号 · CIK
- 0001827090-26-000011
0001827090
营收与利润率
Certara 在 2025 财年 营收为 $419M,同比增长 8.8%。
净利润与每股收益
亏损期间以红色显示。
资本回报率
税后营业利润占投入业务资金(债务加股东权益减现金)的比例。
现金流
2025 财年 的自由现金流为 $94.6M,占营收的 22.6%。 经营现金流减资本支出。
股息、回购与股数
Certara 在 2025 财年 向股东返还 $42.6M,占自由现金流的 45%。 稀释股数增加 0.0%。
自己评估 Certara
调整假设,查看对应的每股价值。这些是模型,不是预测或目标价,结果完全取决于你的输入。
现金流折现
每股价值
—
加上净现金 −$104M,再除以 160.4M 稀释股数。十年现金流加终值,折现至今天。
资产负债表
现金、债务以及显示 Certara 承担债务能力的指标。
| 财年末 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| 现金及短期投资 | $186M | $237M | $235M | $179M | $189M |
| 债务(含融资租赁) | $295M | $293M | $291M | $295M | $293M |
| 净债务 / EBITDA | 7.0x | 1.7x | 3.7x | 1.8x | 1.1x |
| 债务 / 股东权益 | 0.3x | 0.3x | 0.3x | 0.3x | 0.3x |
| 利息保障倍数 | 0.8x | 1.8x | −1.8x | −0.1x | 1.1x |
| 流动比率 | 3.0x | 3.3x | 2.6x | 2.1x | 2.1x |
| 速动比率 | 3.0x | 3.3x | 2.6x | 2.1x | 2.1x |
| 总资产 | $1.5B | $1.6B | $1.6B | $1.6B | $1.6B |
| 总负债 | $470M | $493M | $516M | $516M | $494M |
| 股东权益 | $1.0B | $1.1B | $1.0B | $1.1B | $1.1B |
| 净债务 (− = 净现金) | $109M | $56.4M | $56.2M | $116M | $104M |
内部人交易
高管、董事和持股超过 10% 的股东在公开市场的买卖,数据来自 Form 4 申报。“计划”表示依据事先制定的 Rule 10b5-1 计划进行的交易。
买入(12 个月)
$0.2M
1 名内部人士
卖出(12 个月)
$0.0M
0 名内部人士
卖出中按计划执行的比例
—
$0.0M
| 日期 | 内部人士 | 交易 | 股数 | 股价 | 金额 | 文件 |
|---|---|---|---|---|---|---|
| 2025年11月11日 | William F FeeheryChief Executive Officer, Director | 买入 | 24,096 | $8.30 | $0.2M | Form 4 |
Piotroski F 分数
关于盈利能力、融资和效率的九项通过/未通过测试。8–9 为强,0–2 为弱。
| 测试项 | FY23 | FY24 | FY25 |
|---|---|---|---|
| 净利润为正 | ✕ | ✕ | ✕ |
| 经营现金流为正 | ✓ | ✓ | ✓ |
| 资产回报率上升 | ✕ | ✓ | ✓ |
| 经营现金流高于净利润 | ✓ | ✓ | ✓ |
| 债务相对资产下降 | ✓ | ✕ | ✓ |
| 流动比率上升 | ✕ | ✕ | ✕ |
| 股数未增加 | ✓ | ✕ | ✕ |
| 毛利率上升 | ✕ | — | — |
| 营收相对资产上升 | ✓ | ✓ | ✓ |
| F 分数 | 5 / 9 | 4 / 8 | 5 / 8 |
| 应计比率 | −8.8% | −5.9% | −6.3% |
| Altman Z'' | 2.59 | 2.57 | 2.76 |
相似公司
各公司最近一个财年的数据。各公司财年结束月份不同,因此期间并不完全一致。
| 公司 | 市值 | 增长 | 营业利润率 | 自由现金流利润率 | ROIC | 市盈率 | F 分数 | |
|---|---|---|---|---|---|---|---|---|
| Certara CERT | $1.6B | 8.8% | 5.0% | 22.6% | 0.9% | — | 5 | |
| HealthStream HSTM | $1.0B | 4.3% | 6.7% | 19.6% | — | 48.8x | — | 比较 → |
| Doximity DOCS | $6.4B | 13.1% | 33.3% | 50.6% | 91.3% | 39.3x | 4 | 比较 → |
| Veeva Systems VEEV | $53.3B | 16.3% | 28.7% | 43.4% | — | 52.9x | 6 | 比较 → |
| Solventum SOLV | $14.8B | 0.9% | 26.2% | −0.1% | 20.4% | 10.5x | 5 | 比较 → |
7 年数据
金额单位为 USD。将鼠标悬停在指标名称上可查看定义。
| 财年 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| 利润表 | |||||||
| 营收 | $209M | $244M | $286M | $336M | $354M | $385M | $419M |
| 毛利 | $129M | $143M | $175M | $203M | $213M | — | — |
| 研发支出 | $11.6M | $19.6M | $20.4M | $28.2M | $34.2M | $37.1M | $41.0M |
| 营业利润 | $19.6M | −$24.4M | $13.6M | $32.5M | −$40.8M | −$1.7M | $21.0M |
| 利息支出 | $28.0M | $25.3M | $16.8M | $17.8M | $22.9M | $21.5M | $19.7M |
| 税前利润 | −$9.2M | −$50.2M | −$3.4M | $18.8M | −$55.1M | −$17.2M | $7.6M |
| 所得税 | −$0.2M | −$0.8M | $9.9M | $4.0M | $0.2M | −$5.1M | $9.2M |
| 净利润 | −$8.9M | −$49.4M | −$13.3M | $14.7M | −$55.4M | −$12.1M | −$1.6M |
| 稀释每股收益 | −$0.07 | −$0.37 | −$0.09 | $0.09 | −$0.35 | −$0.08 | −$0.01 |
| 稀释股数 | 0.13B | 0.13B | 0.15B | 0.16B | 0.16B | 0.16B | 0.16B |
| 现金流 | |||||||
| 经营现金流 | $38.0M | $44.8M | $60.4M | $92.5M | $82.8M | $80.5M | $96.3M |
| 资本支出 | $2.1M | $0.9M | $1.1M | $1.4M | $1.8M | $1.6M | $1.8M |
| 自由现金流 | $35.9M | $44.0M | $59.2M | $91.1M | $81.0M | $78.8M | $94.6M |
| 折旧与摊销 | $2.6M | $2.4M | $2.1M | $1.7M | $56.1M | $68.0M | $75.2M |
| 股权激励 | $1.7M | $64.5M | $29.5M | $30.3M | $28.3M | $34.8M | $33.1M |
| 收购 | $0.0M | $0.7M | $261M | $15.3M | $64.2M | $91.3M | $0.0M |
| 股票回购 | $0.7M | $1.1M | $0.0M | $0.0M | $0.0M | $0.0M | $42.6M |
| 已付股息 | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| 股息与回购 | $0.7M | $1.1M | $0.0M | $0.0M | $0.0M | $0.0M | $42.6M |
| 资产负债表 | |||||||
| 现金及短期投资 | $29.3M | $271M | $186M | $237M | $235M | $179M | $189M |
| 总债务 | — | $299M | $295M | $293M | $291M | $295M | $293M |
| 融资租赁负债 | $0.0M | $0.6M | $0.3M | $0.0M | $0.0M | $0.0M | $0.0M |
| 流动资产 | — | $347M | $275M | $342M | $340M | $311M | $315M |
| 流动负债 | — | $75.3M | $92.2M | $103M | $130M | $146M | $153M |
| 存货 | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| 固定资产净额 | — | $3.9M | $2.9M | $2.4M | $2.7M | $2.2M | $1.9M |
| 总资产 | — | $1.3B | $1.5B | $1.6B | $1.6B | $1.6B | $1.6B |
| 总负债 | — | $447M | $470M | $493M | $516M | $516M | $494M |
| 股东权益 | $492M | $822M | $1.0B | $1.1B | $1.0B | $1.1B | $1.1B |
| 利润率 | |||||||
| 毛利率 | 61.7% | 58.6% | 61.0% | 60.5% | 60.2% | — | — |
| 营业利润率 | 9.4% | −10.0% | 4.8% | 9.7% | −11.5% | −0.5% | 5.0% |
| EBITDA 利润率 | 10.7% | −9.0% | 5.5% | 10.2% | 4.3% | 17.2% | 23.0% |
| 净利率 | −4.3% | −20.3% | −4.6% | 4.4% | −15.6% | −3.1% | −0.4% |
| 自由现金流利润率 | 17.2% | 18.1% | 20.7% | 27.2% | 22.9% | 20.5% | 22.6% |
| 回报率 | |||||||
| 资本回报率 | — | — | 1.1% | 2.2% | −2.9% | −0.1% | 0.9% |
| 已动用资本回报率 | — | — | 1.0% | 2.3% | −2.8% | −0.1% | 1.5% |
| 股本回报率 | — | — | −1.4% | 1.4% | −5.2% | −1.1% | −0.2% |
| 资产回报率 | — | — | −1.0% | 1.0% | −3.5% | −0.8% | −0.1% |
| 增长 | |||||||
| 营收增长 | — | 16.8% | 17.5% | 17.3% | 5.6% | 8.7% | 8.8% |
| 净利润增长 | — | — | — | — | −475.8% | — | — |
| 每股收益增长 | — | — | — | — | −488.9% | — | — |
| 自由现金流增长 | — | 22.4% | 34.8% | 53.8% | −11.1% | −2.6% | 19.9% |
| 股数变化 | — | 0.6% | 12.5% | 6.4% | −0.3% | 0.9% | 0.0% |
| 财务健康 | |||||||
| 净债务 / EBITDA | — | — | 7.0x | 1.7x | 3.7x | 1.8x | 1.1x |
| 债务 / 股东权益 | — | 0.4x | 0.3x | 0.3x | 0.3x | 0.3x | 0.3x |
| 利息保障倍数 | 0.7x | −1.0x | 0.8x | 1.8x | −1.8x | −0.1x | 1.1x |
| 流动比率 | — | 4.6x | 3.0x | 3.3x | 2.6x | 2.1x | 2.1x |
| 速动比率 | — | 4.6x | 3.0x | 3.3x | 2.6x | 2.1x | 2.1x |
| 资本配置 | |||||||
| 资本支出 / 营收 | 1.0% | 0.4% | 0.4% | 0.4% | 0.5% | 0.4% | 0.4% |
| 股权激励 / 营收 | 0.8% | 26.5% | 10.3% | 9.0% | 8.0% | 9.0% | 7.9% |
| 股东回报 / 自由现金流 | 2.0% | 2.5% | 0.0% | 0.0% | 0.0% | 0.0% | 45.1% |
| 质量评分 | |||||||
| Piotroski F 分数 | — | — | — | 6.0 | 5.0 | 4.0 | 5.0 |
| Altman Z'' | — | 3.0 | 3.0 | 3.3 | 2.6 | 2.6 | 2.8 |
| 应计比率 | — | — | −5.3% | −5.1% | −8.8% | −5.9% | −6.3% |
来源:SEC EDGAR XBRL 文件 (CIK 0001827090). 数据更新于 2026年10月22日。 第四季度数据为全年减去前九个月。 仅供参考,不构成投资建议。依赖任何数字前,请核对原始文件。




